BALA CYNWYD, Pa. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

BALA CYNWYD, Pa. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index

- Preliminary data   suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg - Company remains on track to report topline data from placebo - controlled single and multiple   ascending dose clinical trials in Q2 2021 BALA CYNWYD, Pa. , Dec.

BALA CYNWYD, Pa. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will

Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich’s ataxia   on track for topline data in 1H   2021 Received orphan drug d esignation for CTI-1601 from the European Commission Cash, cash equivalents, and marketable securities of $102 . 3 million as of September 30, 2020 BALA CYNWYD,

BALA CYNWYD, Pa. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the formation of its Scientific Advisory Board (SAB).

BALA CYNWYD, Pa. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will virtually

BALA CYNWYD, Pa. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will participate in

Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar Therapeutics Phase 1 clinical trial of CTI-1601 for treatment of Friedreich’s ataxia restarts after delay due to COVID-19 related restrictions $80 million private placement financing completed with

BALA CYNWYD, Pa. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will present at the